A Pilot Study of Neoadjuvant Stereotactic Beam Radiation Therapy Followed by Atezolizumab and Bevacizumab in Resectable Hepatocellular Carcinoma
Latest Information Update: 13 Oct 2025
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary)
- Indications Carcinoma; Liver cancer
- Focus Adverse reactions
Most Recent Events
- 01 Oct 2025 Planned End Date changed from 31 Dec 2025 to 29 Apr 2027.
- 01 Oct 2025 Planned primary completion date changed from 31 Dec 2024 to 29 Apr 2026.
- 01 Oct 2025 Status changed from recruiting to active, no longer recruiting.